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Themammalian targetof rapamycin (mTOR)kinase integratescues fromnutrientsandgrowth factors,
acting as a nexus point for cellular signals to control growth,metabolism, and longevity. Deregulation
ofeitherofmTOR’s twocomplexes,mTORC1ormTORC2, leads todiseasesofmetabolism, including
cancer and diabetes. In this issue’s Select, insights into the extent of mTOR’s oncogenic capabilities
come to light, and it appears that an old drug (rapamycin) has some new tricks in vivo.Immunofluorescence ofwild-type (left) and PTENL/L prostate
stained for the proinvasion YB-1 protein, translationally regu-
lated by eIF4E. (Insets) Magnification of individual epithelial
cells. Image courtesy of A. Hsieh.mTOR’s Translational Landscape in
Sickness and in Health
One of mTOR’s key roles is to regulate protein synthesis. But iden-
tifying the full repertoire of mTOR’s translational targets has been
difficult, partly because rapamycin, the most widely used mTOR
inhibitor, does not inhibit all mTOR functions. A class of next-
generation ATP sitemTOR inhibitors in combination with a powerful
new technique, ribosome profiling, is used in two recent studies to
great effect. Thoreen et al. (2012) use transcriptome-wide profiling
in mouse embryonic fibroblasts to define the translational program
in a normal ‘healthy’ setting, and Hsieh et al. (2012) interrogate the
translational networks of a prostate cancer genome in the contextof oncogenic mTOR hyperactivation. Thoreen et al. identify a unifying 50 terminal oligopyrimidine (TOP) or related (TOP-like)
motif in nearly all transcripts specifically regulated by mTORC1 (including a class of transcripts that had not previously been
known as TOPmRNAs), but they find no evidence for a previously postulated theory that mTORC1 regulates the translation of
mRNAswith highly structured and complex 50 untranslated regions (50 UTR). Hsieh et al. uncover a new cis-regulatory element
within the 50 UTR of mTOR-sensitive mRNAs termed the pyrimidine-rich translational element (PRTE). The mechanism of
action that renders TOP, TOP-like, and PRTE-containing transcripts sensitive tomTORC1 regulation is reliant on the inhibitory
eIF4E-binding protein (4E-BP) family of translational repressors. Hsieh et al. focus their attention on prostate cancer, asmTOR
is deregulated in almost all advanced human prostate cancers. They find that a specific set of genes, which cluster into
specific nodes of gene expression important for cancer initiation and progression, is translationally downregulated upon
inhibition of aberrant mTOR signaling. The authors identify and characterize a class of translationally regulated invasion
genes, including CD44 and vimentin, each of which contains a PRTE. The authors go on to develop a clinical-grade ATP
site inhibitor of mTOR, INK128, which effectively decreases the translation of the mTOR-regulated invasion signature and
prevents prostate cancer cell invasion and metastasis in preclinical animal trials. Together, Hsieh et al. and Thoreen et al.
demonstrate that the 4EBP/eIF4E axis plays important roles in both normal physiologic and oncogenic translational
programs, so it will be important to understand how to differentially target the invasive program of cancerous cells without
disrupting mTOR signaling in healthy tissue when developing therapeutic interventions.
Hsieh, A.C., et al. (2012). Nature 485, 55–61.
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with liver-specific knockout of Tsc1
(LTsc1KO) causes a defect in autophagy,
as indicated by increased p62 staining
and aggregation (arrow), which contrib-
utes to liver damage and inflammatory
cell infiltration (I). Image courtesy of B.
Manning.mTORC1 Activation Alone Can Cause Carcinomas
in Mice
Though it is well established that mTOR signaling is often deregulated during cancer
growth, it has been unclear whether the mTOR axis can itself act as a driver of tumor-
igenesis. A study from Menon et al. now provides evidence that simply upregulating
mTORC1 activity by deleting TSC1 in the liver is sufficient to trigger spontaneous
development of hepatocellular carcinomas in mice. TSC1 is an upstream inhibitor
ofmTORC1, and so in its absence,mTORC1 signaling is chronically increased. Before
the onset of overt tumors, liver damage, inflammation, and regenerative proliferation
are visible in the TSC1 liver knockout mice, and these features, as well as the tumors
themselves, are prevented by treatment with the mTORC1 inhibitor rapamycin. ER
stress and aberrant inhibition of autophagy are molecular consequences of chronic
mTORC1 signaling and are both shown to be instrumental in the accumulated cellular
damage in these liver cells. The increase in damaged organelles and the concomitant
decrease in the ability of the cells to process and remove the damage create
a tumorigenic environment predisposing the tissue to cancer. These results areCell 149, May 25, 2012 ª2012 Elsevier Inc. 955
particularly concerning, as the increased mTORC1 activity and early liver damage seen in this experimental setting are remi-
niscent of the hepatic changes induced by obesity. This direct link between increased flux through the nutrient-sensingmTOR
pathway and enhanced rate of carcinogenesis provides support for theories that couple diet to cancer risk.
Menon, S., et al. (2012). Sci. Signal. 5, ra24.Arrowheads point to colocalization of
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and D.H. Kim.A New Member of the Rag-time Band
The Ragulator-Rag GTPase complex recruits mTORC1 to the lysosomal membrane
and is responsible for its ability to sense amino acid availability in the cell. Intriguing
hints for how Rag GTPases sense amino acids are gradually coming into focus.
Recent reports describe an interaction between Ragulator and a vacuolar ATPase
allowing an easy access point to sample the amino acids in the lysosomal lumen;
and an even more direct link to amino acid levels was demonstrated upon identifica-
tion of leucyl-tRNA synthetase as a GAP for RagD. A study from Kim et al. (2012) now
provides a further piece of the puzzle. The authors identify a protein named SH3BP4
that binds to inactive RagGTPase complex in leucine-deprived conditions. SH3BP4
inhibits mTORC1 signaling, suppressing cell growth and promoting autophagy. The
SH3BP4 gene locus is deleted in human breast and renal cancers with a high
frequency, providing another link between deregulated mTOR signaling and tumori-
genesis. The interaction between SH3BP4 and Rag GTPases prevented mTORC1
its recruitment to the lysosome, though how the inhibitory complex interacts with
Ragulator and other components of the amino-acid-sensing machinery is yet to be
determined. As SH3BP4 is known to bind to dynamin, this link provides an intriguingglimpse at global coordination of endosomal trafficking and nutrient sensing at the lysosome.
Kim, Y.M., et al. (2012). Mol. Cell. Published online May 10, 2012. 10.1016/j.molcel.2012.04.007.Rapamycin was discovered in soil samples taken
from Easter Island, or Rapa Nui in Polynesian; the
drug was named accordingly.Two Targets of Rapamycin
As the name indicates, one of the salient features of mTOR kinase action is
that it is inhibited by the small molecule rapamycin. It has been long thought
that only mTORC1 is targeted by rapamycin, inhibiting mTOR’s action on
growth, proliferation, and differentiation, whereas mTORC2, which signals
through the insulin-signaling cascade, is not a pharmacologically relevant
target of the drug. New data from Lamming et al. (2012), however, question
this notion. The authors first wanted to know why, when both caloric restric-
tion (CR) and chronic rapamycin administration (i.e., mTORC1 inhibition) are
known to increase life span in model organisms, the latter treatment reduces
glucose tolerance and insulin action, which is the opposite physiological
effect of CR. Through a series of elegant experiments, the authors show
that mTORC1 inhibition alone cannot account for the changes in glucose
homeostasis seen during rapamycin-induced life span increases in mice.
Instead, disruption of mTORC2 signaling, evidenced by dissociation of
Rictor from mTORC2 and subsequent decrease in phosphorylation of mTORC2 substrates, is essential for the effects of
rapamycin on glucose tolerance. Genetic knockouts that impair mTORC1 function but leave mTORC2 signaling intact
show increased life spans but with normal glucose tolerance and insulin sensitivity. These results suggest that the beneficial
(life span extending) and detrimental (insulin insensitivity) effects of rapamycin can be uncoupled at the level of the mTOR
complex that is targeted, highlighting the potential utility of specific mTORC1 inhibitors.
Lamming, D.W., et al. (2012). Science 335, 1638–1643.
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